The Drugs Controller General of India (DGCI) has approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said.
Source:
Highlights
The first batch of 10,000 doses of the 2-DG drug would be launched early next week, informed DRDO on May 14.
The 2-DG drug helps in faster recovery of the hospitalised COVID-19 patients and reduces oxygen dependence.
New Delhi: The first batch of 10,000 doses of the 2-DG drug for treating COVID-19 patients would be launched early next week, informed Defence Research and Development Organisation officials on Friday (May 14, 2021).
The official informed, The first batch of 10,000 doses of 2-DG medicine for the treatment of COVID-19 infected patients would be launched early next week and will be given to patients. The drug manufacturers are working on ramping up the production of the medicine for future use. The drug has been developed by a team of DRDO scientists including Dr Anant Narayan Bhatt , informed DRDO officials.
Air India ferrying Zeolite for DRDO to boost oxygen production ANI | Updated: May 15, 2021 13:24 IST
By Ashoke Raj
New Delhi [India], May 15 (ANI): To meet the demand of oxygen supply in the country amidst the COVID-19 pandemic, India s Defence Research and Development Organisation (DRDO) has chartered the National Carrier Air India (AI) to import Zeolite from different countries. Government of India is in the process of importing Zeolite from different parts of the world, for use in Pressure Swing Absorption (PSA) plants to boost oxygen supplies in the country. DRDO has been appointed by GOI as a charterer for these consignments. Air India will bring in zeolite for DRDO from different parts of the world, Air India spokesperson told ANI.